CE in anticancer metallodrug research--an update.
With the current demographic development and the knowledge that the probability to be diagnosed with cancer increases with age, the search for new treatment options in cancer chemotherapy is of utmost importance for the society. Capillary electrophoretic methods have been applied in the last few years for studying the properties of metal-based drugs and drug candidates. Especially, the elucidation of the mode of action of such compounds could contribute significantly to design new drugs for overcoming the threat of cancer. This review article highlights the developments in metallodrug research applying CE during the last 4 years and follows a review from 2003 (Hartinger, C. G., Timerbaev, A. R., Keppler, B. K., Electrophoresis 2003, 24, 2023-2037). Most importantly the broadening of application areas of CE must be noted: especially the binding studies of metal complexes toward proteins (including the determination of association and rate constants), following redox reactions of metal complexes and their influence on the reactivity toward biotargets, etc. are important development areas of the last few years. In parallel with these new applications goes the usage of new or modified separation methods including microemulsion EKC or ACE, or the advantageous use of equipping the CE system with mass spectrometric detectors such as inductively coupled plasma (ICP) or ESI mass spectrometers (MS) for determining the degree of metallation of a protein or characterizing the adducts. Finally, upcoming requirements for expanding the method's application area are discussed including studies on new targets in the cell, analyzing real-world samples, methodological development, and contributions to improve the design of new anticancer agents.
Hartinger
Christian G
CG
Institute of Inorganic Chemistry, University of Vienna, Waehringer Strasse 42, A-1090 Vienna, Austria. christian.hartinger@univie.ac.at
Keppler
Bernhard K
BK
D000970:Antineoplastic Agents / Q000737:chemistry / Q000302:isolation & purification*; D002945:Cisplatin / Q000737:chemistry / Q000302:isolation & purification*; D019075:Electrophoresis, Capillary / Q000295:instrumentation / Q000379:methods*; D006801:Humans; D007191:Indazoles / Q000737:chemistry / Q000378:metabolism*; D015394:Molecular Structure; D010984:Platinum / Q000737:chemistry* / Q000378:metabolism; D011485:Protein Binding; D017975:Ruthenium Compounds / Q000737:chemistry / Q000378:metabolism*; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods; D013054:Spectrophotometry, Atomic / Q000295:instrumentation / Q000379:methods; D013237:Stereoisomerism
D000970:Antineoplastic Agents; D007191:Indazoles; D017975:Ruthenium Compounds; D010984:Platinum; D002945:Cisplatin